Peripheral_JJ Blood_NP Lymphocyte_NP Subsets_NP in_IN Adolescents_NP :_: a_DT Longitudinal_JJ Analysis_NN from_IN the_DT REACH_NP Project_NP Flow_NP cytometry_NN analysis_NN of_IN lymphocyte_NN subset_NN markers_NNS was_VBD performed_VBN for_IN a_DT group_NN of_IN sexually_RB active_JJ ,_, human_JJ immunodeficiency_NN virus_NN (HIV)-negative_JJ adolescents_NNS over_IN a_DT 2-year_JJ period_NN to_TO establish_VB normative_JJ data_NNS ._SENT Data_NNS were_VBD collected_VBN in_IN the_DT REACH_NP Project_NP (_( Reaching_VBG for_IN Excellence_NP in_IN Adolescent_NP Care_NP and_CC Health_NP )_) ,_, a_DT multicenter_NN ,_, longitudinal_JJ study_NN of_IN HIV-positive_JJ and_CC high-risk_JJ HIV-negative_JJ adolescents_NNS ._SENT Two-_NN and_CC three-color_NN flow_NN cytometry_NN data_NNS were_VBD collected_VBN every_DT 6_CD months_NNS for_IN these_DT subjects_NNS ._SENT We_PP determined_VBD the_DT effects_NNS of_IN gender_NN ,_, race_NN ,_, and_CC age_NN on_IN the_DT following_VBG lymphocyte_NN subset_NN markers_NNS :_: total_JJ CD4+_NP cells_NNS ,_, CD4+_NP naive_JJ cells_NNS ,_, CD4+_NP memory_NN cells_NNS ,_, all_DT CD8+_NP cells_NNS ,_, CD8+_NP naive_JJ cells_NNS ,_, CD8+_NP memory_NN cells_NNS ,_, CD16+_NP natural_JJ killer_NN cells_NNS ,_, and_CC CD19+_NP B_NP cells_NNS ._SENT Gender_NN was_VBD the_DT demographic_JJ characteristic_NN most_RBS frequently_RB associated_VBN with_IN differences_NNS in_IN lymphocyte_NN subset_NN measures_NNS ._SENT Females_NPS had_VBD higher_JJR total_JJ CD4+_NP cell_NN and_CC CD4+_JJ memory_NN cells_NNS counts_NNS and_CC lower_JJR CD16+_NP cell_NN counts_NNS than_IN males_NNS ._SENT Age_NN was_VBD associated_VBN with_IN higher_JJR CD4+_NP memory_NN cell_NN counts_VBZ as_RB well_RB as_IN higher_JJR CD8+_NP memory_NN cell_NN counts_NNS ._SENT For_IN CD19+_NP cells_NNS ,_, there_EX was_VBD an_DT interaction_NN between_IN age_NN and_CC gender_NN ,_, with_IN males_NNS having_VBG significantly_RB lower_JJR CD19+_NP cell_NN counts_VBZ with_IN increasing_VBG age_NN ,_, whereas_IN there_EX was_VBD no_DT age_NN effect_NN for_IN females_NNS ._SENT Race_NN and/or_CC ethnicity_NN was_VBD associated_VBN with_IN differences_NNS in_IN total_JJ CD8+_NP cell_NN counts_NNS and_CC CD8+_JJ memory_NN cell_NN counts_NNS ,_, although_IN both_DT of_IN these_DT associations_NNS involved_VBD an_DT interaction_NN with_IN gender_NN ._SENT The_DT interaction_NN between_IN infection_NN with_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) and_CC immunologic_JJ responses_NNS to_TO infection_NN has_VBZ led_VBN to_TO the_DT development_NN of_IN new_JJ and_CC more_RBR detailed_JJ laboratory_NN methods_NNS ._SENT There_EX are_VBP limited_JJ normative_JJ data_NNS available_JJ for_IN immunologic_JJ assays_NNS and_CC flow_NN cytometry_NN measures_NNS ,_, especially_RB for_IN specific_JJ age_NN populations_NNS ,_, such_JJ as_IN adolescents_NNS ._SENT Adolescence_NN is_VBZ a_DT unique_JJ period_NN of_IN development_NN ,_, characterized_VBN by_IN profound_JJ physiologic_JJ and_CC psychosocial_JJ changes_NNS ._SENT Gender_NN and_CC age_NN differences_NNS in_IN immunologic_JJ cell_NN numbers_NNS and_CC function_NN have_VBP been_VBN observed_VBN for_IN both_DT healthy_JJ and_CC diseased_JJ subjects_NNS ._SENT Studies_NNS of_IN adolescents_NNS and_CC adults_NNS have_VBP demonstrated_VBN gender_NN differences_NNS as_RB well_RB as_IN some_DT age_NN differences_NNS in_IN immune_JJ cell_NN counts_NNS as_RB characterized_VBN by_IN flow_NN cytometry_NN studies_NNS and_CC limited_JJ number_NN of_IN functional_JJ assays_NNS ._SENT Age_NN may_MD be_VB an_DT important_JJ factor_NN influencing_VBG immunologic_JJ responses_NNS to_TO infection_NN ,_, especially_RB in_IN younger_JJR children_NNS .Other_NN factors_NNS ,_, including_VBG race_NN and_CC genetic_JJ characteristics_NNS ,_, may_MD also_RB influence_VB immunologic_JJ cell_NN numbers_NNS ._SENT Understanding_VBG how_WRB these_DT factors_NNS influence_VBP the_DT immune_JJ system_NN in_IN healthy_JJ individuals_NNS is_VBZ key_JJ to_TO beginning_VBG to_TO understand_VB age_NN ,_, gender_NN ,_, and_CC race_NN differences_NNS in_IN immune_JJ system-based_JJ diseases_NNS and_CC the_DT adolescent_NN 's_POS immunologic_JJ response_NN to_TO infection_NN with_IN HIV_NP and_CC other_JJ infectious_JJ agents_NNS ._SENT HIV_NP infection_NN is_VBZ a_DT major_JJ issue_NN confronting_VBG adolescents_NNS ._SENT Recent_JJ data_NNS show_VBP marked_JJ increases_NNS in_IN the_DT number_NN of_IN HIV_NP infections_NNS in_IN adolescents_NNS and_CC young_JJ adults_NNS ,_, especially_RB in_IN the_DT number_NN of_IN infections_NNS due_JJ to_TO heterosexual_JJ transmission_NN in_IN young_JJ women_NNS and_CC in_IN the_DT number_NN due_JJ to_TO male-to-male_JJ transmission_NN in_IN young_JJ men_NNS ._SENT The_DT REACH_NP (_( Reaching_VBG for_IN Excellence_NP in_IN Adolescent_NP Care_NP and_CC Health_NP )_) Project_NP of_IN AMHARN_NP (_( The_DT Adolescent_JJ Medicine_NP HIV/AIDS_NP Research_NP Network_NP )_) recruited_VBD and_CC longitudinally_RB followed_VBD a_DT cohort_NN of_IN high-risk_JJ youths_NNS not_RB infected_VBN with_IN HIV_NP to_TO establish_VB normative_JJ data_NNS for_IN this_DT population_NN ._SENT The_DT study_NN set_VBD out_RP to_TO establish_VB gender_NN ,_, age_NN ,_, and_CC racial_JJ differences_NNS in_IN a_DT set_NN of_IN immunologic_JJ markers_NNS in_IN a_DT longitudinal_JJ analysis_NN ._SENT Before_IN comparisons_NNS can_MD be_VB made_VBN for_IN HIV-infected_JJ adolescents_NNS ,_, normative_JJ data_NNS must_MD be_VB established_VBN for_IN groups_NNS related_VBN to_TO age_NN ,_, race_NN and/or_CC ethnicity_NN ,_, and_CC gender_NN ._SENT We_PP present_VBP data_NNS for_IN a_DT group_NN of_IN phenotypic_JJ markers_NNS in_IN an_DT HIV-negative_JJ adolescent_JJ cohort_NN ._SENT The_DT REACH_NP Project_NP recruited_VBD HIV-positive_JJ and_CC high-risk_JJ HIV-negative_JJ adolescents_NNS (_( age_NN range_NN ,_, >=13_JJ to_TO <19_JJ years_NNS )_) into_IN a_DT study_NN of_IN biomedical_JJ and_CC behavioral_JJ features_NNS of_IN HIV_NP infection_NN as_IN observed_JJ while_NN under_IN medical_JJ care_NN for_IN HIV_NP infection_NN and_CC adolescent_JJ health_NN ._SENT The_DT HIV-negative_JJ subjects_NNS served_VBN to_TO establish_VB adolescent_JJ normative_JJ data_NNS for_IN a_DT number_NN of_IN biological_JJ measures_NNS ._SENT HIV-negative_JJ subjects_NNS were_VBD recruited_VBN from_IN adolescent_JJ clinics_NNS serving_VBG high-risk_JJ adolescents_NNS based_VBN on_IN the_DT high_JJ seroprevalence_NN rates_NNS in_IN the_DT geographic_JJ areas_NNS and_CC on_IN sexual_JJ risk_NN or_CC needle-using_NN risk_NN of_IN the_DT adolescents_NNS ._SENT The_DT characteristics_NNS of_IN the_DT cohort_NN ,_, recruitment_NN and_CC eligibility_NN criteria_NNS ,_, and_CC study_NN design_NN have_VBP been_VBN reported_VBN elsewhere_RB ._SENT The_DT HIV-negative_JJ subjects_NNS were_VBD determined_VBN to_TO be_VB so_RB on_IN the_DT basis_NN of_IN results_NNS from_IN an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) performed_VBD within_IN 30_CD days_NNS of_IN enrollment_NN into_IN the_DT REACH_NP study_NN ._SENT The_DT HIV_NP ELISA_NP was_VBD repeated_VBN annually_RB to_TO confirm_VB HIV-negative_JJ status_NN ._SENT The_DT HIV-negative_JJ youth_NN ,_, to_TO qualify_VB for_IN enrollment_NN into_IN the_DT study_NN ,_, had_VBD a_DT history_NN of_IN either_DT sexual_JJ intercourse_NN or_CC injection_NN drug_NN use_NN ._SENT Blood_NN samples_NNS for_IN HIV-negative_JJ subjects_NNS were_VBD collected_VBN at_IN 15_CD clinical_JJ sites_NNS every_DT 6_CD months_NNS (_( see_VB Appendix_NNS )_) ._SENT The_DT following_VBG flow_NN markers_NNS were_VBD analyzed_VBN ,_, along_RB with_IN an_DT automated_JJ differential_NN count_NN ,_, at_IN a_DT local_JJ AIDS_NP Clinical_NP Trials_NP Group-certified_NP laboratory_NN :_: CD3+/CD4+_NP (_( helper_NN T_NN cell_NN )_) ,_, CD3+/CD8+_NP (_( suppressor_NN and/or_CC cytotoxic_JJ T_NN cell_NN )_) ,_, CD3-/CD56+/CD16+_NP (_( natural_JJ killer_NN cell_NN )_) ,_, and_CC CD19+_NP (_( total_JJ B_NN cell_NN )_) ._SENT Additional_JJ flow_NN markers_NNS were_VBD analyzed_VBN centrally_RB at_IN the_DT Immunology_NP Core_NP Laboratory_NP at_IN The_DT Children_NP 's_POS Hospital_NP of_IN Philadelphia_NP ,_, as_RB previously_RB reported_VBN ._SENT These_DT markers_NNS included_VBD the_DT following_VBG cell_NN subsets_NNS :_: CD4+/CD45RO-/CD45RA+_NP (_( naive_JJ helper_NN cell_NN )_) ,_, CD4+/CD45RO+/CD45RA-_NP (_( memory_NN helper_NN cell_NN )_) ,_, CD8+/CD45RO-/CD45RA+_NP (_( naive_JJ suppressor_NN cell_NN )_) ,_, and_CC CD8+/CD45RO+/CD45RA-_NP (_( memory_NN suppressor_NN cell_NN )_) ._SENT A_DT cross-sectional_JJ analysis_NN of_IN 192_CD subjects_NNS by_IN two-sided_JJ tests_NNS with_IN a_DT type_NN I_PP error_NN of_IN 5_CD %_NN and_CC a_DT power_NN of_IN 80_CD %_NN can_MD identify_VB a_DT standardized_JJ effect_NN of_IN 0.20_CD ,_, considered_VBN small_JJ ,_, or_CC a_DT correlation_NN of_IN 0.20_CD ._SENT Repeated_JJ analyses_NNS ,_, with_IN subject_NN 's_POS age_NN at_IN the_DT data_NNS collection_NN visit_NN as_IN the_DT time_NN variable_NN ,_, were_VBD performed_VBN using_VBG Generalized_JJ Estimating_JJ Equations_NNS (_( GEE_NP )_) software_NN (_( SAS_NP software_NN ,_, version_NN 8.1_CD ;_: [_SYM SAS_NP Institute_NP ]_SYM )_) ._SENT P_NN values_NNS of_IN 0.05_CD or_CC less_JJR were_VBD considered_VBN significant_JJ for_IN two-sided_JJ tests_NNS ._SENT Multiple_JJ comparison_NN corrections_NNS were_VBD not_RB used_VBN ._SENT Summary_NN statistics_NNS for_IN cell_NN counts_NNS are_VBP presented_VBN as_IN means_NNS and_CC standard_JJ deviations_NNS ,_, which_WDT include_VBP only_RB one_CD observation_NN per_IN subject_NN in_IN each_DT age_NN category_NN ,_, although_IN individual_JJ subjects_NNS may_MD have_VB contributed_VBN to_TO more_JJR than_IN one_CD age_NN category_NN ._SENT For_IN analysis_NN ,_, counts_NNS were_VBD log-transformed_VBN to_TO make_VB skewed_JJ distributions_NNS more_RBR nearly_RB normal_JJ ,_, as_RB assessed_VBN by_IN the_DT Shapiro-Wilks_NP test_NN ._SENT Separately_RB for_IN each_DT lymphocyte_NN subset_NN ,_, GEE_NP models_NNS were_VBD used_VBN to_TO regress_VB log_NN counts_NNS on_IN gender_NN ,_, subject_NN 's_POS present_JJ age_NN ,_, and_CC race_NN and/or_CC ethnicity_NN of_IN these_DT HIV-negative_JJ subjects_NNS ._SENT The_DT three_CD two-way_JJ interactions_NNS of_IN the_DT demographic_JJ variables_NNS were_VBD also_RB examined_VBN ;_: models_NNS with_IN interactions_NNS also_RB retained_VBD main_JJ effects_NNS ._SENT Because_IN multiple_JJ visits_NNS in_IN the_DT same_JJ age_NN category_NN were_VBD included_VBN ,_, these_DT GEE_NP models_NNS used_VBD more_JJR data_NNS than_IN appear_VBP in_IN the_DT summary_NN of_IN means_NNS and_CC standard_JJ deviations_NNS ._SENT At_IN the_DT time_NN of_IN this_DT analysis_NN ,_, 198_CD HIV-negative_JJ subjects_NNS were_VBD enrolled_VBN in_IN the_DT REACH_NP cohort_NN ._SENT Two_CD HIV-negative_JJ transgender_NN males_NNS were_VBD excluded_VBN and_CC 4_CD subjects_NNS did_VBD not_RB have_VB a_DT complete_JJ lymphocyte_NN subset_NN panel_NN evaluation_NN performed_VBD ,_, leaving_VBG 192_CD subjects_NNS eligible_JJ for_IN analysis_NN ._SENT The_DT demographic_JJ characteristics_NNS of_IN the_DT eligible_JJ subjects_NNS are_VBP shown_VBN in_IN Table_NP ._SENT For_IN each_DT eligible_JJ subject_NN ,_, all_DT study_NN visits_NNS at_IN which_WDT a_DT complete_JJ lymphocyte_NN subset_NN panel_NN evaluation_NN had_VBD been_VBN performed_VBN were_VBD included_VBN in_IN the_DT analysis_NN ._SENT The_DT total_JJ number_NN of_IN study_NN visits_NNS included_VBD was_VBD 779_CD ,_, with_IN one_CD to_TO nine_CD visits_NNS per_IN subject_NN ._SENT The_DT distribution_NN of_IN ages_NNS at_IN the_DT times_NNS the_DT visits_NNS were_VBD made_VBN is_VBZ also_RB shown_VBN in_IN Table_NP ._SENT The_DT means_NNS and_CC standard_JJ deviations_NNS by_IN gender_NN and_CC age_NN for_IN each_DT of_IN the_DT eight_CD subsets_NNS are_VBP provided_VBN in_IN Table_NP ._SENT Figures_NNS to_RB are_VBP a_DT graphical_JJ display_NN of_IN means_NNS by_IN gender_NN and_CC age_NN ._SENT The_DT significant_JJ statistical_JJ associations_NNS ,_, by_IN cell_NN type_NN ,_, are_VBP shown_VBN in_IN Table_NP ._SENT There_EX was_VBD a_DT significant_JJ association_NN with_IN one_CD or_CC more_JJR of_IN the_DT demographic_JJ characteristics_NNS for_IN 6_CD of_IN the_DT 8_CD lymphocyte_NN subsets_NNS that_WDT were_VBD examined_VBN ._SENT No_DT association_NN with_IN the_DT three_CD demographic_JJ characteristics_NNS was_VBD found_VBN for_IN CD4+_NP naive_JJ cells_NNS or_CC for_IN CD8+_NP naive_JJ cells_NNS ._SENT Gender_NN was_VBD the_DT demographic_JJ characteristic_NN most_RBS frequently_RB associated_VBN with_IN differences_NNS in_IN lymphocyte_NN subset_NN counts_NNS ._SENT Gender_NN had_VBD a_DT significant_JJ main_JJ effect_NN or_CC interaction_NN for_IN 6_CD of_IN the_DT 8_CD subsets_NNS :_: total_JJ CD4+_NP cells_NNS ,_, CD4+_NP memory_NN cells_NNS ,_, total_JJ CD8+_NP cells_NNS ,_, CD8+_NP memory_NN cells_NNS ,_, CD16+_NP cells_NNS ,_, and_CC CD19+_NP cells_NNS ._SENT Females_NPS had_VBD higher_JJR total_JJ CD4+_NP cell_NN counts_NNS ,_, higher_JJR CD4+_NP memory_NN cell_NN counts_NNS ,_, and_CC lower_JJR CD16+_NP cell_NN counts_NNS ._SENT For_IN total_JJ CD8+_NP cells_NNS and_CC CD8+_JJ memory_NN cells_NNS ,_, there_EX was_VBD an_DT interaction_NN between_IN gender_NN and_CC race_NN ._SENT African-American_NP males_NNS had_VBD significantly_RB lower_JJR total_JJ CD8+_NP counts_NNS than_IN did_VBD other_JJ males_NNS ;_: there_EX was_VBD not_RB a_DT significant_JJ difference_NN in_IN total_JJ CD8+_NP counts_NNS by_IN race_NN for_IN females_NNS ,_, although_IN African-American_NP females_NNS had_VBD nearly_RB significantly_RB higher_JJR total_JJ CD8+_NP counts_NNS ._SENT For_IN CD8+_NP memory_NN cells_NNS ,_, African-American_NP and_CC Hispanic_JJ males_NNS had_VBD higher_RBR mean_VB counts_NNS than_IN males_NNS classified_VBN as_IN Caucasian_JJ or_CC other_JJ ,_, while_IN African-American_NP and_CC Hispanic_JJ females_NNS had_VBD lower_RBR mean_VB counts_NNS than_IN females_NNS classified_VBN as_IN Caucasian_JJ or_CC other_JJ ._SENT None_NN of_IN these_DT differences_NNS were_VBD statistically_RB significant_JJ when_WRB data_NNS for_IN males_NNS and_CC females_NNS were_VBD modeled_VBN separately_RB ._SENT For_IN CD19+_NP cells_NNS ,_, there_EX was_VBD an_DT interaction_NN between_IN gender_NN and_CC age_NN ._SENT Males_NNS had_VBD significantly_RB lower_JJR CD19+_NP cells_NNS counts_NNS with_IN increasing_VBG age_NN ,_, whereas_IN there_EX was_VBD no_DT age_NN effect_NN for_IN females_NNS ._SENT Age_NN was_VBD associated_VBN with_IN differences_NNS in_IN three_CD of_IN the_DT eight_CD subsets_NNS :_: CD4+_JJ memory_NN cells_NNS ,_, CD8+_NP memory_NN cells_NNS ,_, and_CC CD19+_NP cells_NNS ._SENT Older_JJR subjects_NNS had_VBD higher_JJR CD4+_NP memory_NN cell_NN counts_NNS and_CC higher_JJR CD8+_NP memory_NN cell_NN counts_NNS ._SENT The_DT gender_NN by_IN age_NN interaction_NN for_IN CD19+_NP cells_NNS is_VBZ described_VBN in_IN the_DT preceding_JJ paragraph_NN ._SENT Race_NN and/or_CC ethnicity_NN was_VBD associated_VBN with_IN differences_NNS in_IN only_RB two_CD of_IN the_DT eight_CD subsets_NNS :_: total_JJ CD8+_NP cells_NNS and_CC CD8+_JJ memory_NN cells_NNS ._SENT Both_CC of_IN these_DT associations_NNS involved_VBD an_DT interaction_NN with_IN gender_NN ,_, as_RB was_VBD discussed_VBN above_IN ._SENT FIG.1_NP ._SENT |_SYM Graphical_JJ representation_NN of_IN peripheral_JJ blood_NN lymphocyte_NN subsets_NNS (_( CD4_NP cells_NNS )_) observed_VBN in_IN adolescents_NNS ._SENT Graphical_JJ representation_NN of_IN peripheral_JJ blood_NN lymphocyte_NN subsets_NNS (_( CD4_NP cells_NNS )_) observed_VBN in_IN adolescents_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Graphical_JJ representation_NN of_IN peripheral_JJ blood_NN lymphocyte_NN subsets_NNS (_( CD16_NP and_CC CD19_NP cells_NNS )_) observed_VBN in_IN adolescents_NNS ._SENT Graphical_JJ representation_NN of_IN peripheral_JJ blood_NN lymphocyte_NN subsets_NNS (_( CD16_NP and_CC CD19_NP cells_NNS )_) observed_VBN in_IN adolescents_NNS ._SENT TABLE_NN 1_CD |_SYM Characteristics_NN of_IN the_DT cohort_NN TABLE_NP 2_CD |_SYM Mean_NP counts_NNS (_( and_CC standard_JJ deviations_NNS )_) of_IN lymphocyte_NN subsets_NNS by_IN gender_NN and_CC age_NN TABLE_NP 3_CD |_SYM Significant_JJ associations_NNS between_IN demographic_JJ characteristics_NNS and_CC lymphocyte_NN subsets_NNS ,_, calculated_VBN by_IN multivariate_JJ linear_JJ regression_NN We_PP have_VBP investigated_VBN the_DT impact_NN of_IN gender_NN ,_, race_NN ,_, and_CC age_NN on_IN T-lymphocyte_NP subset_NN populations_NNS as_RB measured_VBN by_IN flow_NN cytometry_NN in_IN adolescents_NNS identified_VBN as_IN at_IN high_JJ risk_NN for_IN HIV_NP infection_NN in_IN a_DT national_JJ ,_, longitudinal_JJ study_NN ._SENT Gender_NN was_VBD the_DT demographic_JJ factor_NN most_RBS frequently_RB associated_VBN with_IN differences_NNS in_IN lymphocyte_NN subsets_NNS ._SENT In_IN females_NNS ,_, we_PP found_VBD higher_JJR CD_NN 4+_JJ T-lymphocyte_NN counts_NNS and_CC higher_JJR CD4+_NP memory_NN T-lymphocyte_NN counts_NNS ,_, and_CC lower_JJR CD_NN 16+_JJ T-lymphocyte_NN counts_VBZ than_IN in_IN males_NNS ._SENT Our_PP$ study_NN demonstrated_VBD some_DT limited_JJ gender_NN differences_NNS in_IN CD8+_NP cells_NNS and_CC CD19+_JJ cells_NNS counts_NNS ,_, but_CC only_RB with_IN the_DT influence_NN of_IN either_DT race_NN or_CC age_NN ._SENT Since_IN this_DT was_VBD a_DT longitudinal_JJ study_NN in_IN a_DT predominantly_RB African-American_NP and_CC Hispanic_JJ group_NN of_IN adolescents_NNS ,_, it_PP serves_VBZ as_IN an_DT important_JJ reference_NN when_WRB studying_VBG disease_NN processes_NNS that_WDT affect_VBP the_DT immune_JJ system_NN in_IN the_DT adolescent_JJ population_NN ._SENT Our_PP$ data_NNS for_IN CD4+_NP T_NN lymphocyte_NN differences_NNS by_IN gender_NN are_VBP consistent_JJ with_IN those_DT previously_RB reported_VBN for_IN minority_NN and_CC Caucasian_JJ adolescents_NNS ._SENT Bartlett_NP and_CC colleagues_NNS studied_VBD a_DT group_NN of_IN minority_NN youth_NN and_CC found_VBD higher_JJR levels_NNS (_( both_CC totals_NNS and_CC percentages_NNS )_) of_IN CD4+_NP T_NN lymphocytes_NNS in_IN females_NNS than_IN in_IN males_NNS and_CC lower_JJR levels_NNS of_IN B_NP cells_NNS in_IN females_NNS than_IN in_IN males_NNS ._SENT In_IN another_DT study_NN of_IN primarily_RB Caucasian_JJ adolescents_NNS from_IN 12_CD to_TO 19_CD years_NNS ,_, Tollerud_NP and_CC colleagues_NNS found_VBD higher_JJR levels_NNS of_IN CD4+_NP T_NN lymphocytes_NNS in_IN females_NNS than_IN in_IN males_NNS among_IN older_JJR adolescents_NNS ._SENT Our_PP$ studies_NNS demonstrate_VBP that_IN much_RB of_IN this_DT gender_NN difference_NN is_VBZ mainly_RB in_IN the_DT memory_NN CD4+_NP T-cell_NN subset_NN ._SENT We_PP did_VBD not_RB find_VB significantly_RB higher_JJR B-cell_NN levels_NNS in_IN males_NNS than_IN in_IN females_NNS ,_, as_RB was_VBD found_VBN by_IN Bartlett_NP ._SENT There_EX is_VBZ no_DT direct_JJ explanation_NN for_IN this_DT ;_: however_RB ,_, we_PP had_VBD fewer_JJR adolescents_NNS in_IN the_DT younger_JJR age_NN ranges_NNS ,_, which_WDT may_MD explain_VB some_DT of_IN this_DT difference_NN ._SENT A_DT number_NN of_IN studies_NNS have_VBP reported_VBN increases_NNS in_IN CD4+_NP T_NN cells_NNS in_IN females_NNS ._SENT Studies_NNS of_IN adults_NNS have_VBP identified_VBN some_DT similar_JJ gender_NN differences_NNS ._SENT Higher_JJR mean_NN total_JJ CD3+_NP T-cell_NN and_CC mean_VB total_JJ CD4+_NP T-cell_NN counts_NNS have_VBP been_VBN observed_VBN in_IN females_NNS than_IN in_IN males_NNS ;_: in_IN addition_NN ,_, lower_JJR CD16+_NP cells_NNS have_VBP also_RB been_VBN noted_VBN in_IN adult_JJ females_NNS than_IN in_IN males_NNS ._SENT Differences_NNS in_IN immune_JJ cell_NN numbers_NNS may_MD be_VB secondary_JJ to_TO hormonal_JJ differences_NNS (_( androgens_NNS or_CC estrogen_NN or_CC both_DT )_) ._SENT Gender_NN may_MD affect_VB the_DT immune_JJ system_NN at_IN many_JJ levels_NNS ._SENT Differences_NNS in_IN sex_NN steroid_NN regulation_NN and_CC production_NN are_VBP present_JJ in_IN males_NNS and_CC females_NNS early_RB in_IN development_NN ,_, with_IN the_DT most_RBS profound_JJ differences_NNS noted_VBD during_IN adolescence_NN with_IN the_DT onset_NN of_IN puberty_NN ._SENT Pubertal_JJ hormonal_JJ changes_NNS occur_VBP under_IN the_DT control_NN of_IN the_DT hypothalamic-pituitary-gonadal_JJ axis_NN ,_, which_WDT leads_VBZ to_TO increases_NNS in_IN sex_NN hormone_NN levels_NNS ._SENT Gender_NN has_VBZ an_DT effect_NN on_IN both_DT B-_NP and_CC T-cell_NN responses_NNS and_CC the_DT secretion_NN of_IN immune_JJ modulators_NNS ,_, including_VBG cytokines_NNS and_CC chemokines_NNS ._SENT Cell_NN proliferation_NN occurs_VBZ under_IN the_DT influence_NN of_IN cytokines_NNS ,_, and_CC some_DT differences_NNS in_IN T-cell_NN numbers_NNS between_IN males_NNS and_CC females_NNS may_MD be_VB related_VBN to_TO differences_NNS in_IN cytokine_NN regulation_NN ._SENT Whether_IN the_DT increased_VBN levels_NNS of_IN circulating_VBG CD4+_NP T_NN cells_NNS found_VBN in_IN females_NNS in_IN this_DT study_NN is_VBZ secondary_JJ to_TO the_DT influence_NN of_IN specific_JJ cytokines_NNS requires_VBZ further_JJR investigation_NN ._SENT Sex_NN hormones_NNS may_MD influence_VB the_DT immune_JJ cell_NN populations_NNS through_IN several_JJ indirect_JJ pathways_NNS ._SENT Sex_NN hormones_NNS may_MD impact_VB immune_JJ cell_NN numbers_NNS through_IN thymic_JJ pathways_NNS ._SENT Studies_NNS of_IN castrated_VBN male_JJ mice_NNS demonstrate_VBP increased_VBN number_NN of_IN both_DT CD4+_NP T_NN cells_NNS and_CC CD8+_JJ T_NN cells_NNS ._SENT In_IN addition_NN ,_, evidence_NN suggests_VBZ that_IN thymic_JJ involution_NN is_VBZ modulated_VBN by_IN androgens_NNS ._SENT Sex_NN hormones_NNS may_MD also_RB influence_VB T_NN cells_NNS directly_RB through_IN cell_NN receptors_NNS for_IN sex_NN steroids_NNS ,_, as_RB has_VBZ been_VBN found_VBN for_IN CD8+_NP T_NN cells_NNS ._SENT During_IN adolescence_NN ,_, the_DT hormonal_JJ influence_NN on_IN immune_JJ cell_NN numbers_NNS may_MD be_VB most_RBS apparent_JJ ;_: however_RB ,_, the_DT impact_NN of_IN sex_NN hormones_NNS on_IN immunity_NN may_MD begin_VB much_RB earlier_RBR ._SENT There_EX are_VBP detectable_JJ estrogen_NN receptors_NNS in_IN fetal_JJ thymus_NN as_RB well_RB as_IN fetal_JJ lymphoblast_NN cells_NNS ,_, suggesting_VBG that_IN sex_NN hormones_NNS may_MD influence_VB lymphocyte_NN maturation_NN in_IN the_DT thymus_NN ._SENT Whether_IN the_DT interactions_NNS between_IN lymphocyte_NN receptors_NNS and_CC sex_NN hormones_NNS lead_VBP to_TO differences_NNS in_IN immune_JJ cells_NNS numbers_NNS later_RBR in_IN life_NN is_VBZ not_RB clear_JJ ._SENT Gender_NN differences_NNS in_IN circulating_VBG T-cell_NN subsets_NNS most_RBS likely_RB reflect_VBP a_DT complex_JJ regulatory_JJ mechanism_NN ,_, some_DT of_IN which_WDT may_MD be_VB under_IN the_DT influence_NN of_IN gender_NN differences_NNS in_IN sex_NN steroids_NNS ._SENT The_DT impact_NN of_IN gender_NN on_IN the_DT immune_JJ system_NN is_VBZ evident_JJ from_IN gender_NN differences_NNS in_IN immune_JJ system_NN diseases_NNS particularly_RB autoimmune_JJ disorders_NNS ._SENT Systemic_JJ lupus_NN erythematosis_NN ,_, rheumatoid_JJ arthritis_NN ,_, myasthenia_NN gravis_NNS ,_, and_CC Hashimoto_NP 's_POS disease_NN all_RB have_VBP a_DT higher_JJR prevalence_NN among_IN women_NNS ._SENT We_PP found_VBD no_DT independent_JJ influences_NNS of_IN race_NN and/or_CC ethnicity_NN on_IN any_DT of_IN the_DT immunologic_JJ measures_NNS in_IN our_PP$ study_NN ._SENT We_PP are_VBP limited_VBN ,_, however_RB ,_, by_IN the_DT relatively_RB small_JJ numbers_NNS of_IN Caucasion_NN subjects_NNS in_IN our_PP$ cohort_NN ._SENT Rates_NNS of_IN new_JJ HIV_NP infections_NNS in_IN adolescents_NNS appear_VBP to_TO be_VB greatest_JJS in_IN minority_NN groups_NNS ._SENT Thus_RB ,_, racial_JJ or_CC ethnic_JJ differences_NNS in_IN immune_JJ responses_NNS would_MD be_VB important_JJ to_TO determine_VB in_IN a_DT more_RBR heterogeneous_JJ population_NN ._SENT We_PP also_RB found_VBD limited_JJ influence_NN of_IN age_NN on_IN the_DT T-cells_NNS subsets_NNS studied_VBN with_IN the_DT only_JJ independent_JJ impact_NN of_IN age_NN on_IN memory_NN CD4+_NP T_NN cells_NNS and_CC CD8+_JJ T_NN cells_NNS ._SENT Again_RB ,_, our_PP$ study_NN is_VBZ limited_VBN by_IN small_JJ numbers_NNS of_IN younger_JJR adolescent_JJ subjects_NNS ._SENT Studies_NNS in_IN younger_JJR children_NNS show_VBP a_DT significant_JJ impact_NN of_IN age_NN on_IN T-cell_NN populations_NNS ,_, with_IN signficantly_RB higher_JJR numbers_NNS of_IN CD4+_NP T_NN lymphocytes_NNS in_IN young_JJ infants_NNS ._SENT Differences_NNS between_IN adolescents_NNS and_CC adults_NNS have_VBP been_VBN reported_VBN :_: adolescent_JJ females_NNS begin_VBP to_TO demonstrate_VB CD4+_NP T-cell_NN levels_NNS that_WDT are_VBP increased_VBN compared_VBN to_TO those_DT observed_VBN in_IN males_NNS ,_, and_CC females_NNS also_RB begin_VBP to_TO demonstrate_VB CD8+_NP T_NN cell_NN levels_NNS that_WDT are_VBP lower_JJR (_( such_JJ levels_NNS in_IN adults_NNS have_VBP also_RB been_VBN reported_VBN )_) ._SENT Our_PP$ numbers_NNS may_MD be_VB too_RB small_JJ to_TO demonstrate_VB subtle_JJ differences_NNS in_IN the_DT transition_NN from_IN adolescence_NN to_TO adulthood_NN ._SENT Our_PP$ study_NN is_VBZ unique_JJ as_IN a_DT longitudinal_JJ analysis_NN of_IN gender_NN ,_, age_NN ,_, and_CC race_NN and/or_CC ethnicity_NN differences_NNS in_IN specific_JJ immunologic_JJ cells_NNS in_IN high-risk_JJ youth_NN ._SENT Although_IN we_PP found_VBD some_DT significant_JJ differences_NNS ,_, our_PP$ study_NN has_VBZ several_JJ limitations_NNS ._SENT First_RB ,_, as_IN most_JJS of_IN our_PP$ youth_NN were_VBD sexually_RB mature_JJ at_IN the_DT time_NN of_IN entry_NN into_IN the_DT study_NN ,_, we_PP were_VBD unable_JJ to_TO analyze_VB the_DT data_NNS by_IN Tanner-stage_NP subgroups_NNS ._SENT Second_RB ,_, the_DT mechanisms_NNS leading_VBG to_TO gender_NN differences_NNS were_VBD beyond_IN the_DT scope_NN of_IN this_DT study_NN ._SENT Finally_RB ,_, our_PP$ population_NN was_VBD primarily_RB minority_NN ;_: thus_RB ,_, the_DT findings_NNS may_MD not_RB apply_VB to_TO all_DT populations_NNS ._SENT However_RB ,_, understanding_VBG the_DT impact_NN of_IN gender_NN ,_, race_NN ,_, and_CC age_NN on_IN immune_JJ cell_NN numbers_NNS in_IN healthy_JJ individuals_NNS is_VBZ essential_JJ for_IN subsequent_JJ evaluation_NN in_IN disease_NN states_NNS ._SENT The_DT following_VBG investigators_NNS ,_, listed_VBN in_IN order_NN by_IN the_DT numbers_NNS of_IN subjects_NNS enrolled_VBN at_IN their_PP$ respective_JJ clinics_NNS ,_, are_VBP participating_VBG in_IN this_DT study_NN :_: L._NP Friedman_NP ,_, L._NP Pall_NP ,_, D._NP Maturo_NP ,_, A._NP Pasquale_NP (_( University_NP of_IN Miami_NP )_) ;_: D._NP Futterman_NP ,_, D._NP Monte_NP ,_, M._NP Alovera-DeBellis_NP ,_, N._NP Hoffman_NP ,_, and_CC S._NP Jackson_NP (_( Montefiore_NP Medical_NP Center_NP )_) ;_: D._NP Schwarz_NP and_CC coauthor_VB B._NP Rudy_NP (_( University_NP of_IN Pennsylvania_NP and_CC the_DT Children_NP 's_POS Hospital_NP of_IN Philadelphia_NP )_) ;_: M._NP Tanney_NP and_CC A._NP Feldman_NP (_( Children_NP 's_POS Hospital_NP of_IN Philadelphia_NP )_) ;_: M._NP Belzer_NP ,_, D._NP Tucker_NP ,_, C._NP Hosmer_NP ,_, K._NP Chung_NP (_( Children_NP 's_POS Hospital_NP of_IN Los_NP Angeles_NP )_) ;_: S._NP E._NP Abdalian_NP ,_, L._NP Green_NP ,_, C._NP McKendall_NP ,_, and_CC L._NP Wenthold_NP (_( Tulane_NP Medical_NP Center_NP )_) ;_: L._NP J._NP D'Angelo_NP ,_, C._NP Trexler_NP ,_, C._NP Townsend-Akpan_NP ,_, R._NP Hagler_NP ,_, and_CC J._NP A._NP Morrissy_NP (_( Children_NP 's_POS National_NP Medical_NP Center_NP )_) ;_: L._NP Peralta_NP ,_, C._NP Ryder_NP ,_, S._NP Miller_NP ,_, and_CC S._NP Calianno_NP (_( University_NP of_IN Maryland_NP )_) ;_: L._NP Henry-Reid_NP and_CC R._NP Camacho_NP (_( Cook_NP County_NP Hospital/University_NP of_IN Chicago_NP )_) ;_: M._NP Sturdevant_NP ,_, A._NP Howell_NP ,_, and_CC J._NP E._NP Johnson_NP (_( Children_NP 's_POS Hospital_NP ,_, Birmingham_NP )_) ;_: A._NP Puga_NP ,_, D._NP Cruz_NP ,_, and_CC P._NP McLendon_NP (_( Children_NP 's_POS Diagnostic_NP and_CC Treatment_NP Center_NP )_) ;_: M._NP Sawyer_NP ,_, J._NP Tigner_NP ,_, and_CC A._NP Simmonds_NP (_( Emory_NP University_NP )_) ;_: P._NP Flynn_NP ,_, K._NP Lett_NP ,_, J._NP Dewey_NP ,_, S._NP Discenza_NP (_( St._NP Jude_NP Children_NP 's_POS Research_NP Hospital_NP )_) ;_: L._NP Levin_NP and_CC M._NP Geiger_NP (_( Mt_NP ._SENT Sinai_NP Medical_NP Center_NP )_) ;_: P._NP Stanford_NP and_CC F._NP Briggs_NP (_( University_NP of_IN Medicine_NP and_CC Dentistry_NP of_IN New_NP Jersey_NP )_) ;_: and_CC J._NP Birnbaum_NP ,_, M._NP Ramnarine_NP ,_, and_CC V._NP Guarino_NP (_( SUNY_NP Health_NP Science_NP Center_NP at_IN Brooklyn_NP )_) ._SENT The_DT following_VBG investigators_NNS have_VBP been_VBN responsible_JJ for_IN the_DT basic_JJ science_NN agenda_NN :_: C._NP Holland_NP (_( Center_NP for_IN Virology_NP ,_, Immunology_NN ,_, and_CC Infectious_NP Disease_NP ,_, Children_NP 's_POS Research_NP Institute_NP ,_, Children_NP 's_POS National_NP Medical_NP Center_NP )_) ,_, A._NP B._NP Moscicki_NP (_( University_NP of_IN California_NP at_IN San_NP Francisco_NP )_) ,_, D._NP A._NP Murphy_NP (_( University_NP of_IN California_NP at_IN Los_NP Angeles_NP )_) ;_: S._NP H._NP Vermund_NP (_( University_NP of_IN Alabama_NP at_IN Birmingham_NP )_) ;_: P._NP Crowley-Nowick_NP (_( The_DT Fearing_NP Laboratory_NP ,_, Brigham_NP and_CC Women_NP 's_POS Hospital_NN ,_, and_CC Harvard_NP Medical_NP School_NP ,_, Boston_NP ,_, Mass._NP )_) ,_, coauthor_NN S._NP D._NP Douglas_NP (_( University_NP of_IN Pennsylvania_NP and_CC the_DT Children_NP 's_POS Hospital_NP of_IN Philadelphia_NP )_) ._SENT Staff_NN from_IN sponsoring_VBG agencies_NNS include_VBP A._NP Rogers_NP and_CC A._NP Willoughby_NP ,_, (_( NICHD_NP )_) ,_, K._NP Davenny_NP and_CC V._NP Smeriglio_NP (_( NIDA_NP )_) ,_, E._NP Matzen_NP ,_, (_( NIAID_NP )_) ,_, B._NP Vitiello_NP (_( NIMH_NP )_) ._SENT 